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Lupus-related myelopathy: report of three cases
and review of the literature
James Provenzale, ThomasW Bouldin
Abstract
Transverse myelopathy is an uncommon
complication of systemic lupus erythema-
tosus (SLE). Three patients with SLE are
reported who developed transverse mye-
lopathy, including the neuropathological
findings in one patient on whom necropsy
was performed. Paraparesis was present
in all three cases, but definite sensory
changes were present in only one patient.
In two patients, the CSF findings were
remarkable for elevated protein and
depressed glucose concentrations. Micro-
scopic examination of the brain demon-
strated small, scattered foci of recent
necrosis consistent with microinfarctions.
Striking abnormalities were found in the
spinal cord at all levels, including multiple
foci of vacuolar spongy degeneration in
the peripheral white matter, as well as
ballooning of myelin sheaths, swollen
axons, myelin pallor, and loss of glial
nuclei. The pathological findings in pre-
viously reported cases of SLE-related
transverse myelopathy are reviewed, and
the possible pathogenesis ofthe findings in
our case are discussed.
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Although CNS complications of systemic
lupus erythematosus (SLE) are common,'
descriptions of myelopathy related to SLE are
relatively rare. Reported cases of lupus-related
myelopathy have, for the most part, been
notable for poor recovery and a high mortality
rate. Three cases of myelopathy related to SLE
have been treated at the North Carolina
Memorial Hospital over a ten year period,
which suggests that this condition is not as rare
as the medical literature would indicate. We
report these cases, including the pathological
findings in one case.
Case reports
Case one
A 21 year old black woman developed
intermittent fevers, night sweats, anorexia, a
generalised rash and diffuse lymphadenopathy
in February 1983. Initial serological studies for
SLE were negative, and she was given a
diagnosis of seronegative SLE. The rash res-
ponded to prednisone, 30 mg four times a day.
Subsequently she was found to have a high-
titre speckled ANA and antibody to SS-A and
RNP. She was treated with hydroxy-
chloroquine for three months, and steroids
were tapered to a low maintenance dose eight
months after onset of symptoms.
Two years later, she developed fever, flank
pain and malaise, and steroids were increased
to 20 mg daily. She also developed progressive
gait difficulty over the next three weeks and
experienced three generalised seizures. She
had no urinary symptoms but bowel move-
ments were decreased.
Neurological examination revealed moder-
ate lethargy, poor short-term memory, normal
cranial nerve examination, full strength in the
arms without pronator drift but 2/5 strength
diffusely in both legs. Cerebellar and sensory
examination were normal. She was treated
with phenytoin and phenobarbital. CT head
scan showed moderate cerebral atrophy.
Myelographic examination of the entire spinal
cord was normal. The lumbar puncture
revealed clear, colourless fluid, with 0 RBC, 0
WBC, glucose 79 mg% (no simultaneous
serum glucose), and protein 71 mg%. The
erythrocyte sedimentation rate was 130 mm/
hr, and the peripheral white blood cell count
was 1000/cu mm. The initial diagnosis was
lupus cerebritis and her prednisone was
increased to 40 mg daily. Over the next week,
her paraparesis worsened, with absent deep
tendon reflexes in the legs and extensor plantar
responses, although strength in her arms was
unaffected. She was treated with methylpred-
nisolone 25 mg twice a day.
One week later, she experienced a sudden
hypotensive episode, and needed ventilatory
support. She became increasingly disoriented.
A repeat lumbar puncture showed clear,
colourless fluid, 10 RBC, 0 WBC, glucose
110 mg% (simultaneous serum glucose
236 mg%) and protein 67 mg%. Transverse
myelitis secondary to SLE was considered the
most likely diagnosis. She died after a res-
piratory arrest one week later, five weeks after
onset of neurological symptoms.
At necropsy, gross examination of the brain
revealed slight atherosclerotic changes of the
arteries of the circle of Willis and no brain
atrophy. The cranial nerves were unremark-
able. A shaggy fibrinous exudate was present
on the dura mater of the spinal cord. The gross
appearance of the spinal cord was unremark-
able. The cut surfaces of the brain and spinal
cord showed no focal lesions. Microscopic
examination of the brain revealed scattered
microscopic foci of recent necrosis consistent
with microinfarcts in the cerebral cortex, basal
ganglia, thalamus and brainstem. The blood
vessels in the effected areas of the brain often
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Figure 1 Anterior
funiculus of lumbar spinal
cord from case 1. Multiple
areas of spongy
degeneration are present in
the subpial white matter
along the median fissure.




exhibited mural thickening with reactive endo-
thelial cells. Occasional blood vessels had
perivascular chronic inflammatory infiltrates,
but neither necrotising arteritis, nor thrombi
nor emboli were identified.
The most striking microscopic abnormalities
in the spinal cord were multiple foci of spongy
degeneration of the white matter in the peri-
phery of the spinal cord (fig 1). These lesions
were seen at all levels of the spinal cord but
were most frequent at the lumbar level (fig 2).
Similar spongy degeneration of the white
matter was also focally present in the medulla.
The lateral funiculus, especially the dorso-
lateral region, was involved at all levels. The
posterior columns were relatively spared, while
the anterior funiculus showed variable degrees
of involvement, most severe at the lumbar
level. There was no evidence of ascending or
descending tract degeneration. The anterior
horn cells and nerve roots were intact at all
levels. The blood vessels surrounding the
spinal cord did not reveal vasculitis, perivas-
cular infiltrates, thrombi or emboli.
At higher magnification, the areas of spongy
degeneration showed clear vacuoles and swol-
len axons (fig 3). Many vacuoles appeared to
be surrounded by a thin rim of myelin,
suggesting that these vacuoles represented
ballooning of myelin sheaths. In some foci,
occasional foamy macrophages were also pres-
ent. The largest of the spongy lesions also
showed pallor of myelin and pyknosis and loss
of glial nuclei.
Case two
A 15 year old black female developed arthral-
gias, fatigue, fever and weight loss in 1984, and
found to have an ESR of 148, low C3, C4 and
CH 50 titres, an ANA positive at 1:640 with a
speckled pattern, and a positive rheumatoid
factor at 1:640. Over the following year, she
developed renal failure secondary to
membraneous glomerulnephritis and pleural
effusions despite treatment with prednisone
60 mg daily. Her steroids were tapered over the
next year to a low maintenance dose, but in late
1986 she developed confusion, dysarthria,
slowly progressive leg weakness and pain, and
urinary incontinence over the course of three
weeks. At the time of admission to hospital
three weeks after the onset of leg weakness, she
was able to ambulate only with assistance.
Short-term memory and calculations were
poor. She had dysarthric speech but no other
significant cranial nerve findings. Strength was
rated 4/5 in the arms, 2/5 at the hips and 3/5 at
the knees. Deep tendon reflexes were hyperac-
tive in the arms, with clonus at both knees and
both ankles, and bilateral extensor plantar
responses. Cerebellar and sensory examina-
tions were normal. Her rectal sphincter tone
was normal.
A lumbar puncture showed one red blood
cell, seven white blood cells, glucose 41 mg%
(no simultaneous serum glucose) and protein
248 mg%. CSF gram stain showed no organ-
isms, and CSF culture and AFB stain were
negative. MRI of the brain and entire spinal
cord revealed significant cerebral atrophy but
no other abnormalities.
The patient was treated with 60 mg daily of
prednisone, but her confusion and leg weak-
ness continued to worsen. She was given
methylprednisolone 250 mg intravenous four
times a day for three days without improve-
ment. Visual and brainstem auditory evoked
potentials were normal. Upper extremity
somatosensory evoked potentials were normal
while lower extremity somatosensory evoked
potentials were abnormal bilaterally. A repeat
lumbar puncture revealed clear, colourless
fluid, with 2 RBC, 1 WBC, glucose 65 mg%
(simultaneous serum glucose 142 mg%) and
protein 41 mg%. The CSF/serum IgG/albumin
index was 2-91 (normal range 0-34-088) and
oligoclonal bands were noted in the CSF but
not in the serum.
The patient had a series of 11 plasma
exchange procedures over the course of the
next four weeks, supplemented by an infusion
of 0-75 grams of cyclophosphamide at one
week. At the time of discharge three weeks
after beginning plasma exchange therapy, sig-
nificant improvement in the patient's ence-
phalopathy was noted, with moderate
improvement in leg strength and urinary blad-
der function. At the time of discharge she was
able to walk with the aid of a walker.
The patient subsequently had another pulse
infusion of 0 7 grams of cyclophosphamide
and a single plasma exchange procedure one
month after discharge. She was maintained on
60 mg prednisone daily. Six months after the
onset of leg weakness, she was able to walk
without a walker, could climb stairs with






















- Severe vacuolar change
Figure 2 Schematic representation demonstrating the distribution of subpial vacuolar
changes within the spinal cord white matter tracts at various levels.
Case three
A 15 year old black female developed a papular
erythematous rash over her arms in 1977, and
soon after experienced arthralgias, diffuse
Figure 3 Region of white mater degeneration in anterior fasciculus of thoracic spinal
cord exhibiting clear vacuoles rimmed by myelin. The dense, homogeneous structure near
the centre of the field is a swollen axon. There is pyknosis and loss ofglial nuclei,
suggesting glial-ce,U necrosis and dropout (x 380; Solochrome-eosin stain).
weakness and alopecia. Laboratory studies
showed a greatly elevated CPK as well as a
positive LE prep of 1:2000, an ANA titre of
1:320, a negative rheumatoid factor and neg-
ative double-stranded DNA tests. An elec-
tromyogram showed polyphasia and reduced
motor unit duration and a muscle biopsy was
diagnostic of an inflammatory myopathy. She
was diagnosed as having SLE and polymyo-
sitis. The patient was treated with 60 mg
prednisone daily with significant improvement
and was tapered to low maintenance doses over
the next year.
One year later, she developed low back pain,
bilateral leg weakness and urinary incon-
tinence which progressed over three weeks
before admission to hospital. Her neurological
examination revealed normal strength in the
arms, but 3/5 strength throughout the legs. She
had normal reflexes in the arms but absent
knee and ankle jerk reflexes, and bilateral
extensor plantar responses. There was hypaes-
thesia to pinprick over the L3 to S5 derma-
tomes. The cerebellar examination was
normal. A lumbar myelogram revealed no
abnormalities. The CSF showed the following
values: 206 RBC, 20WBC (87% lymphocytes
and 13% monocytes), glucose 46 mg% (no
simultaneous serum glucose obtained) and
protein 254 mg%.
The diagnosis of myelopathy related to SLE
was made and her prednisone dosage was
increased to 60 mg daily. A repeat CSF exam-
ination a week later showed 52 red blood cells,
84 white blood cells (80% lymphocytes, 20%
monocytes), glucose 105 mg% with simultane-
ous serum glucose of 139 mg%, and protein of
261. The CSF/serum IgG/albumin ratio was
0-685, and the fluid was positive for the
presence ofmyelin basic protein. She improved
slowly over the next two months and at
discharge was able to walk with the aid of a
walker, with significant resolution of sensory
dysfunction, although a neurogenic bladder
was still present. At six months after onset of
neurological symptoms, she continued to show
moderate leg weakness on low daily doses of
prednisone, on which she is presently main-
tained.
Discussion
CNS complications ofSLE have been reported
to occur at some point in the majority of SLE
cases.2 These include focal neurological find-
ings such as cranial neuropathy, hemiparesis
and hemisensory loss, as well as nonfocal
changes such as psychosis, memory loss, dis-
turbance of affect, and generalised seizures.
However, lupus-related myelopathy, that is,
quadriparesis or paraparesis, sensory changes
in the extremities, and bowel and bladder
dysfunction due to spinal cord involvement,
has not been commonly reported. A review of
the literature reveals a description of only 31
cases. Histopathological findings have been
reported in less than half of these cases.
Myelopathic features do not preclude the
possibility of other CNS abnormalities, and in
cases where seizures or disturbance of menta-
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tion accompany spinal cord-related symptoms
and signs, the clinical syndrome is best des-
cribed by the term "encephalomyelopathy".
The most characteristic presentation of
lupus-related myelopathy in a patient with
previously diagnosed SLE is the development
of bilateral leg weakness and sensory changes
with bowel and bladder dysfunction. These
findings are almost invariably present.3 Signs
referrable to a cervical spinal cord lesion,
including bilateral arm weakness, have also
been reported.3 However, paraparesis is much
more commonly seen than quadraparesis.
Occasionally neck or back pain of a rather
significant degree is also present.4 Because
these symptoms may mimic those of a space-
occupying spinal cord lesion, such as an
abscess, haematoma or neoplasm, myelo-
graphy or MRI may be indicated in individual
cases.5
Extensor plantar responses have been found
in 12 of 18 cases in which they have been
recorded, including all three patients in our
series. Sensory changes are described in almost
all reported cases, with a mid- or low-thoracic
sensory level being described most often.
Incomplete sensory loss has been reported in a
number of cases. In addition, occasionally
sensory loss only in the sacral dermatomes has
been reported, as in one of our cases. As
illustrated in our first two cases, sensory loss
need not be present. In the first case, inability
to determine loss of all sensory modalities may
be partly due to the difficulty in examining a
severely encephalopathic patient. There is no
singular characteristic change in the reflexes in
the affected extremities. While some patients
will have significantly diminished or absent
reflexes, even in the setting of extensor plantar
reflexes, some cases will have increased
reflexes. As our cases illustrate, there may be a
combination of diminished knee jerk reflexes
and prominently increased ankle jerk reflexes.
The rate of onset is usually over the course of
a few days to a week, although it is not
uncommon for the neurological changes to
develop over a few weeks. The interval from
onset of SLE to the development of myelo-
pathy varies from several months to a few years
in most cases, although the presence of SLE
symptoms up to 23 years before the onset of
myelopathy has been reported.6 In rare instan-
ces, myelopathy has been reported as the first
major manifestation of systemic lupus erythe-
matosus,78 while in other cases there may have
been other organ system involvement suggest-
ing SLE without a definitive diagnosis.
The CSF formula is almost always abnormal
at some point after the onset of myelopathy.
The review by Warren and Kredich3 revealed
elevated CSF protein levels in 14 of 17
patients, depressed CSF glucose levels (below
30 mg%) in six of 12 patients, and a CSF
pleocytosis of more than 20 cells/mm, usually
lymphocytes, in 10 of 14 patients. The CSF
protein levels were abnormally elevated (above
40 mg%) in all of our patients at some point in
their clinical course, but the degree of elevation
differed significantly between cases and did not
necessarily reflect the level of clinical involve-
ment. In only one of our cases was the CSF
glucose below 50 mg%, although in case num-
ber one the CSF glucose was less than half of a
simultaneous serum glucose level. Unfortu-
nately, data regarding the serum glucose at the
time of lumbar puncture are lacking in some of
our cases and in most of the reported cases.
Only one of our three cases showed a CSF
pleocytosis of greater than 20 cells. CSF
complement levels were not obtained in any of
our cases but were reported to be depressed in
two cases in the series ofWarren and Kredich.8
In summary, CSF abnormalities are common
in lupus-related myelopathy, but the abnor-
malities are nonspecific and often mild.
Because of the nonspecific CSF abnormalities,
and because these patients are often taking
immunosuppressive drugs before the onset of
myelopathy, bacterial, viral and fungal infec-
tions always need to be considered in the
differential diagnosis.
Three types of pathological changes have
been reported in lupus-related myelopathy
(table). In the first, there is extensive spinal
cord softening limited to a specific cord level,
and accompanied by vascular alterations rang-
ing from perivasculitis to fibrinoid arteritis to
thrombosis. Sinkovics,9 Piperl0 and Adrian-
akos" have each reported cases in which there
was extensive spinal cord infarction at a spe-
cific cord level.
The second type of pathological change
associated with lupus-related myelopathy is a
large subdural haematoma at a spnal cord
level, unaccompanied by vasculopathy. There
are two reported cases of myelopathy second-
ary to subdural haematoma and spinal cord
compression in patients with SLE (table). In
one case there were multiple small haemor-
rhages within the substance of the spinal
cord,'2 and in the other, there was necrosis of
the underlying spinal cord parenchyma."3
The most common type of pathological
change reported in cases of SLE-related mye-
lopathy is peripheral white-matter degen-
eration, often at multiple spinal cord levels. We
have termed this characteristic pattern of
spinal cord degeneration "subpial leukomye-
lopathy" because of its peripheral location and
its primary involvement of white matter. These
lesions show ballooning of myelin sheaths and
axonal degeneration similar to that seen in our
first case. Spinal-cord tract degeneration is not
seen in these cases. As opposed to the extensive
spinal cord destruction at a specific cord level
in the type I category, the extent of the spinal
cord degeneration at any one level in subpial
leukomyelopathy may appear relatively insig-
nificant. The fact that the lesions result in the
clinical presentation of paraparesis or quad-
riparesis and significant sensory abnormalities
is apparently due to a summation effect.
Previously reported cases of subpial leuk-
omyelopathy are outlined in the table. Vacuolar
changes were reported at all spinal cord levels
in a number of these cases, although in Fisher's
patient the changes were primarily at the
thoracic and lumbar levels.'4 Andrews et al 6
did not describe the characteristic peripheral
distribution of vacuolar changes but their case
833
4Provenzale, Bouldin
Table Pathological findings in lupus myelopathy
Author (citation) Gross pathological findings Microscopic findings
Type I Large spinal cord infarct
Sinkovics9 Spinal cord softening and loss of Infarction pattern with thrombosis of anterior spinal
cord substance at lumbar level. artery.
Acute fibrinoid necrosis of wall of anterior spinal artery.
Cryptococcal meningeal infiltrate.
Piper'0 Fusiform swelling of spinal cord at Myelomalacia of posterior horns. Fibrinoid change and
lumbar level. perivascular infiltrate in adjacent meningeal vessels.
Thrombi in surrounding vessels.
Adrianakos" Large necrotic lesion throughout Necrosis of grey and white matter at thoracic spinal cord
middle thoracic cord segments. level. Ascending and descending tract degeneration at
other spinal cord levels.
Perivascular connective tissue proliferation. Lymphocytic
and mononuclear cell infiltrates around small venules.
No evidence of occlusive lesion.
Type II Spinal cord subdural hemawoma
Johns Hopkins CPC'2 Two large subdural haematomas Multiple small haemorrhages within substance of spinal
compressing lower spinal cord. cord and dorsal root ganglia. No evidence of arteritis.
Weil"3 Subdural haematoma extending Necrosis of underlying spinal cord.
over low thoracic and upper
lumbar spinal cord.
Type III Subpial leukomyelopathy
Andrews6 Loss of spinal cord substance at Areas of necrosis at all spinal cord levels, with
thoracic and lumbar spinal cord replacement by lipid-filled macrophages. No evidence
levels. of vasculitis.
Fisher'4 Loss of spinal cord substance at Ballooning of myelin sheaths in peripheral white matter at
lumbar levels. thoracic and lumbar levels. Edema and neuronal
degeneration in grey matter. Haemorrhage in many
Virchow-Robin spaces.
Gold and Yahrl'7 Not described. Peripherally placed white matter degeneration involving
entire spinal cord circumference.
Johnson and Richardson' Not described. Disruption of both myelin and axis cylinders. Vacuoles of
varying sizes showing swollen myelin sheaths at border
of normal and abnormal parenchyma. No evidence of
vasculitis.
Penn and Rowan'6 Multiple peripheral areas of Loss of nerve fibres and occasional swollen and
rarefaction of thoracic spinal degenerated axons.
cord white matter.
Nakano" Case I: Multiple rounded lesions in Marked spongy changes and swollen axons. Focal areas of
periphery of spinal cord at all necrosis, various stages of fibrinoid necrosis or
levels. organised thrombus in peripheral vessels.
Case H: Marked pallor of Prominent axonal loss and gliosis in spinal cord
peripheral areas in circumferen- periphery. Diffuse vascular changes in peripheral
tial distribution. arachnoid arteries including severe intimal thickening
and fibrinoid necrosis.
is included because, unlike those cases out-
lined under the Type 1 and Type 2 categories,
there was spinal cord degeneration at multiple
levels as well as the absence of vascular
abnormalities. Nakano"5 described areas of
marked axonal degeneration in the periphery
of the spinal cord white matter in two patients
with SLE-related transverse myelopathy,
including focal regions of spongy change and
swollen axons similar to the findings in our
necropsy case. However, Nakano also reported
vascular changes, including fibrinoid necrosis
and severe intimal thickening and foamy cell
infiltration, in the small arachnoid arteries of
the spinal cords of both patients. Examination
of the spinal cord vasculature in our case did
not reveal similar changes.
It is not clear whether the three types of
pathological changes in the spinal cord in
lupus-related myelopathy are due to separate
or common pathogenetic mechanisms. The
primary abnormality in the first type of spinal
cord degeneration, that is, a large infarct,
seems to be due to thrombosis superimposed
upon necrotising arteritis. Whether a primary
defect ofthe vessel wall, such as some degree of
fibrinoid necrosis leading to vascular weaken-
ing, is also present in the cases of spinal cord
subdural haematoma is open to speculation.
However, fibrinoid necrosis of the vessel wall
was not mentioned in either of the two
reported cases of spinal cord subdural haema-
toma. Penn and Rowan"6 speculated that
subdural haemorrhage in these cases may be
secondary to a coagulopathy, for example, due
to circulating lupus anticoagulant, in which
case a primary mural abnormality need not be
implicated.
The pathogenesis of the subpial leuk-
omyelopathy in SLE is also uncertain. Gold
and Yahr'7 suggested that the pathological
changes reported in their case were due to an
autoimmune mechanism causing direct paren-
chymal damage. A circulating factor in the
CSF might account for the peripheral distribu-
tion of the vacuolar changes seen in these
cases, but such a factor has never been
identified.
Similar vacuolar changes have been
described in AIDS-related myelopathy.
Petito"8 described these changes in 29% of
consecutive necropsy cases of AIDS. The
vacuolar degeneration was more prominent in
patients with severe myelopathy. The changes
were reported to be distributed throughout the
spinal cord white matter, but were more
prominent in the lateral columns. Like the
changes seen in SLE, these abnormalities were
not confined to specific anatomical tracts. As in
the SLE cases, the vacuoles were surrounded
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by a thinned myelin sheath, suggesting that
they were formed by intramyelin swelling.
Similar findings have subsequently been des-
cribed by other investigators."9 None of the
patients in our series were known to have been
exposed to any of the risk factors for AIDS,
and neither of the two surviving patients has
subsequently developed AIDS-like symptoms.
The peripheral distribution of the white
matter degeneration in the spinal cord is
similar to that described by Bunge and Sett-
lage20 following CSF barbotage in cats. A
similar peripheral pattern of degeneration in
spinal cord, brainstem and optic tracts was
reported by Friede and Roessman2' in a
patient who had repeated lumbar punctures for
a CSF leak following transsphenoidal hypohy-
sectomy. Winkelman22 also reported peripheral
spongy degeneration of the spinal cord follow-
ing accidental intrathecal injection of detergent
solutions during administration of spinal
anaesthesia.
The possibility that these lesions are secon-
dary to ischaemia must also be considered.
Nakano 5 reported fibrinoid necrosis and
severe intimal thickening in arterioles surroun-
ding the spinal leukomyelopathy. Similar vas-
cular changes were not found in our case or the
other previously reported cases and the subpial
location of the changes is not the typical
location of spinal cord infarcts. Thus there is
little support for the hypothesis that these
lesions are related to ischaemia.
In summary, lupus myelopathy may present
with a variety of signs and symptoms, which
may initially lead to misdiagnosis. Although
paraparesis appears to be a constant feature,
there is great variability regarding sensory
disturbance and changes in the reflexes. There
is also great variability in the CSF findings.
Pathological findings similar to those seen in
our first case have been previously described,
and may be characteristic of lupus myelitis,
although not pathognomonic of it. Unfortun-
ately, at present, the pathogenesis of these
findings is poorly understood.
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